To address these gaps, we conducted a retrospective cohort study in NIU patients treated with ADA, aiming to evaluate the levels and incidence of AAAs, characterize serum ADA concentrations and their association with clinical responses, and preliminarily assess the clinical utility of TDM in this setting. The gene discussed is ADA; the disease is achalasia-alacrima syndrome.